Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON24917
NL-OMON24917
Recruiting
Not Applicable

Phase II trial of the combination of gemcitabine and 131I-MIBG therapy in paediatric patients with relapsed or progressive neuroblastoma.

Academisch Medisch Centrum Amsterdam0 sites66 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsneuroblastoma, children, relapsed, progressive

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
neuroblastoma, children, relapsed, progressive
Sponsor
Academisch Medisch Centrum Amsterdam
Enrollment
66
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

/A

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Academisch Medisch Centrum Amsterdam

Eligibility Criteria

Inclusion Criteria

  • •1\. Histological proven neuroblastoma;
  • •2\. Measurable primary and/or metastatic disease;

Exclusion Criteria

  • •1\. Received treatment within the last 21 days with an
  • •investigational or conventional anti\-cancer drug;

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Phase II trial of the combination of gemcitabine and 131I-MIBG therapy in paediatric patients with relapsed or progressive neuroblastoma
NL-OMON39557Academisch Medisch Centrum16
Active, not recruiting
Not Applicable
A phase II study of the combination of gemcitabine with 131I-MIBG therapy for children with neuroblastoma without other treatment options.relapsed or progressive neuroblastoma in pediatric patients of 1 to 18 yearsTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2007-007974-45-NLAMC47
Unknown
Phase 1
Phase 1/2 study of the combination of gemcitabine and nedaplation for treatment of previously untreated advanced squamous cell lung cancerPreaviously untreated advanced advanced squamous cell lung cancer
JPRN-C000000439Department of Respiratory Medicine of Kyoto University Hospital32
Completed
Phase 2
Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural MesotheliomaMesothelioma, Malignant
NCT02303899Istituto Clinico Humanitas22
Active, not recruiting
Phase 1
Phase 2 single-arm studies of gemcitabine in combination with oxaliplatin in refractory and relapsed pediatric solid tumors. - ITCC-004-GEMOXRefractory or relapsing malignant pediatric solid tumors.
EUCTR2006-001065-41-GBniversity Hospitals of Leicester NHS Trust, Research and Development Directorate156